To standardize the use of phototherapy consistent with the American Academy of Pediatrics clinical practice guideline for the management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
INTRODUCTION
Clinical trials have validated the efficacy of phototherapy in reducing excessive unconjugated hyperbilirubinemia, and its implementation has drastically curtailed the use of exchange transfusions. 1 The initiation and duration of phototherapy is defined by a specific range of total bilirubin values based on an infant's postnatal age and the potential risk for bilirubin neurotoxicity. 1 Clinical response to phototherapy depends on the efficacy of the phototherapy device as well as the balance between an infant's rates of bilirubin production and elimination. The active agent in phototherapy is light delivered in measurable doses, which makes phototherapy conceptually similar to pharmacotherapy. This report standardizes the use of phototherapy consistent with the American Academy of Pediatrics clinical practice guideline for the management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
I. COMMERCIAL LIGHT SOURCES
A wide selection of commercial phototherapy devices is available in the United States. A complete discussion of devices is beyond the scope of this review; some are described in Tables  1 and 2 . Phototherapy devices can be categorized according to their light source as follows: (1) fluorescent-tube devices that emit different colors (cool white daylight, blue [B] , special blue [BB] , turquoise, and green) and are straight (F20 T12, 60 cm, 20 W), U-shaped, or spiral-shaped; (2) metal halide bulbs, used in spotlights and incubator lights; (3) light-emitting diodes (LEDs) or metal halide bulbs, used with fiber-optic light guides in pads, blankets, or spotlights; and (4) high-intensity LEDs, used as over-and under-the-body devices. Data in Table 1 are expanded and updated from that previously reported by Vreman et al. 3 The definitions and standards for device assessment are explained below.
EMISSION SPECTRAL QUALITIES: Measured data of the light delivered by each of the light sources are presented as the minimum, maximum and range. Light source emission spectra within the range of 300 -700 nm were recorded after the device had reached stable light emission, using a miniature fiberoptic radiometer (IRRAD2000, Ocean Optics, Inc, Dunedin, FL). For precision based device assessment, the spectral bandwidth (*), which is defined as the width of the emission spectrum in nm at 50% of peak light intensity, is the preferred method to distinguish and compare instead of the total range emission spectrum (data usually provided by manufacturers). Emission peak values are also used to characterize the quality of light emitted by a given light source. IRRADIANCE: Measured data are presented as mean Ϯ standard deviation (SD), representing the irradiance of blue light (including spectral bandwidth), for each device's light footprint at the manufacturer-recommended distance. To compare diverse devices, the spectral irradiance (W/cm2/nm) measurements were made using calibrated BiliBlanket Meters I and II (Ohmeda, GE Healthcare, Fairfield, CT), which were found to yield identical results with stable output phototherapy devices. This type of meter was selected from the several devices with different photonic characteristics that are commercially available, because it has a wide sensitivity range (400 -520 nm with peak sensitivity at 450 nm), which overlaps the bilirubin absorption spectrum and which renders it suitable for the evaluation of narrow and broad wavelength band light sources. The devices have been found exceptionally stable during several years of use and agree closely after each annual calibration. FOOTPRINT: The minimum and maximum irradiance measured (at the intervals provided or defined) in the given irradiance footprint of the device (length ϫ width). The footprint of a device is that area which is occupied by a patient to receive phototherapy. The irradiance footprint has greater dimensions than the emission surface, which is measured at the point where the light exits a phototherapy device. The minimum and maximum values are shown to indicate the range of irradiances encountered with a device and can be used as an indication of the uniformity of the emitted light. Most devices conform to an international standard to deliver a minimum/maximum footprint light ratio of no lower than 0.4.
BSA: BODY SURFACE AREA refers to percent (%) exposure of either the ventral or dorsal planar surface exposed to light and Irradiance measurements are accurate to Ϯ0.5.
All of the reported devices are marketed in the United States except the PortaBed, which is a non-licensed Stanford-developed research device and the Dutch Crigler-Najjar Association (used by Crigler-Najjar patients). Table 1 lists technical data for some of the devices marketed in the United States. 3 Factors to consider in prescribing and implementing phototherapy are (1) emission range of the light source, (2) the light intensity (irradiance), (3) the exposed ("treatable") body surface area illuminated, and (4) the decrease in total bilirubin concentration. A measure of the effectiveness of phototherapy to rapidly configure the bilirubin molecule to less toxic photoisomers (measured in seconds)
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II. STANDARDS FOR PHOTOTHERAPY DEVICES
is not yet clinically available.
A. Light Wavelength
The visible white light spectrum ranges from approximately 350 to 800 nm. Bilirubin absorbs visible light most strongly in the blue region of the spectrum (ϳ460 nm). Absorption of light transforms unconjugated bilirubin molecules bound to human serum albumin in solution into bilirubin photoproducts (predominantly isomers of bilirubin). 2, 4, 5 Because of the photophysical properties of skin, the most effective light in vivo is probably in the blue-to-green region (ϳ460 -490 nm). 2 The first prototype phototherapy device to result in a clinically significant rate of bilirubin decrease used a blue (B) fluorescent-tube light source with 420-to 480-nm emission. 6, 7 More effective narrow-band special blue bulbs (F20T12/BB [General Electric, Westinghouse, Sylvania] or TL52/20W
[Phillips]) were subsequently used. 8, 9 Most recently, commercial compact fluorescent-tube light sources and devices that use LEDs of narrow spectral bandwidth have been used. 9-14 Unless specified otherwise, plastic covers or optical filters need to be used to remove potentially harmful ultraviolet light.
Clinical Context
Devices with maximum emission within the 460-to 490-nm (blue-green) region of the visible spectrum are probably the most effective for treating hyperbilirubinemia. 2, 4 Lights with broader emission also will work, although not as effectively. Special blue (BB) fluorescent lights are effective but should not be confused with white lights painted blue or covered with blue plastic sheaths, which should not be used. Devices that contain highintensity gallium nitride LEDs with emission within the 460-to 490-nm regions are also effective and have a longer lifetime (Ͼ20 000 hours), lower heat output, low infrared emission, and no ultraviolet emission.
B. Measuring Light Irradiance
Light intensity or energy output is defined by irradiance and refers to the number of photons (spectral energy) that are delivered per unit area (cm 2 ) of exposed skin. 1 The dose of phototherapy is a measure of the irradiance delivered for a specific duration and adjusted to the exposed body surface area. Determination of an in vivo doseresponse relationship is confounded by the optical properties of skin and the rates of bilirubin production and elimination. 1 Irradiance is measured with a radiometer (W·cm Ϫ2 ) or spectroradiometer (W·cm Ϫ2 ·nm Ϫ1 ) over a given wavelength band. 
Clinical Context
Physical obstruction of light by equipment, such as radiant warmers, head covers, large diapers, eye masks that enclose large areas of the scalp, tape, electrode patches, and insulating plastic covers, decrease the exposed skin surface area. Circumferential phototherapy maximizes the exposed area. Combining several devices, such as fluorescent tubes with fiber-optic pads or LED mattresses placed below the infant or bassinet, will increase the surface area exposed. If the infant is in an incubator, the light rays should be perpendicular to the surface of the incubator to minimize reflectance and loss of efficacy. 1,2
D. Rate of Response Measured by Decrease in Serum Bilirubin Concentration
The clinical impact of phototherapy should be evident within 4 to 6 hours of initiation with an anticipated decrease of more than 2 mg/dL (34 mol/L) in serum bilirubin concentration. 1 The clinical response depends on the rates of bilirubin production, enterohepatic circulation, and bilirubin elimination; the degree of tissue bilirubin deposition 15, 16, 18 ; and the rates of the photochemical reactions of bilirubin. Aggressive implementation of phototherapy for excessive hyperbilirubinemia, sometimes referred to as the "crash-cart" approach, 19, 20 has been reported to reduce the need for exchange transfusion and possibly reduce the severity of bilirubin neurotoxicity.
Clinical Context
Serial measurements of bilirubin concentration are used to monitor the effectiveness of phototherapy, but the value of these measurements can be confounded by changes in bilirubin production or elimination and by a sudden increase in bilirubin concentration (rebound) if phototherapy is stopped. Periodicity of serial measurements is based on clinical judgment.
III. EVIDENCE FOR EFFECTIVE PHOTOTHERAPY
Light-emission characteristics of phototherapy devices help in predicting FROM THE AMERICAN ACADEMY OF PEDIATRICS their effectiveness (group B recommendation) (see Appendix). The clinical effectiveness of the device should be known before and monitored during clinical application (group B recommendation). Local guidelines (instructions) for routine clinical use should be available. Important factors that need to be considered are listed in Table 3 . Obstructing the light source and reducing the exposed body surface area must be avoided (group B recommendation).
These recommendations are appropriate for clinical care in high-resource settings. In low-resource settings the use of improvised technologies and affordable phototherapy device choices need to meet minimum efficacy and safety standards. 
IV. SAFETY AND PROTECTIVE MEASURES
V. RESEARCH NEEDS
Among the gaps in knowledge that remain regarding the use of phototherapy to prevent severe neonatal hyperbilirubinemia, the following are among the most important:
1. The ability to measure the actual wavelength and irradiance delivered by a phototherapy device is urgently needed to assess the efficiency of This intervention is not recommended. There is a moderate to high certainty that the intervention has no net benefit and that the harms outweigh the benefits Discourage use of this intervention I The current evidence is insufficient to assess the balance of benefits against and harms of this intervention. There is a moderate to high certainty that the intervention has no net benefit and that the harms outweigh the benefits. Evidence is lacking, of poor quality, or conflicting, and the balance of benefits and harms cannot be determined If this intervention is conducted, the patient should understand the uncertainty about the balance of benefits and harms US Preventive Services Task Force Grade definitions, May, 2008 (available at www.uspreventiveservicestaskforce.org/3rduspstf/ratings.htm).
